Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin liposome + CapOX + Bevacizumab in SMAD4-mutated CRC
NCT06753721Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in colorectal adenocarcinoma, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Progression-Free Survival at 6 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT06753721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06753721.